FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (39)
2024
-
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)
Clinical and Translational Oncology
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 8, pp. 1587-1594
-
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
European urology oncology, Vol. 6, Núm. 1, pp. 58-66
-
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
The oncologist, Vol. 28, Núm. 1, pp. 23-32
-
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664
2022
-
Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS
Dermatology, Vol. 238, Núm. 2, pp. 320-328
-
Incomplete Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery)
Journal of the European Academy of Dermatology and Venereology
-
Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer –Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 5, pp. 451-458
2021
-
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin
Molecular Oncology, Vol. 15, Núm. 12, pp. 3691-3705
-
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial
JAMA Oncology, Vol. 7, Núm. 12, pp. 1791-1799
-
Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3116-3125
-
Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature
Experimental dermatology, Vol. 30, Núm. 5, pp. 717-722
-
Mutational characterization of cutaneous melanoma supports divergent pathways model for melanoma development
Cancers, Vol. 13, Núm. 20
-
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
EBioMedicine, Vol. 69
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455
-
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Breast, Vol. 54, pp. 286-292
-
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 456-466